Here's the latest on the companies leading the race to end the coronavirus pandemic.
- On July 16, Pfizer PFE and BioNTech announced they expect a decision by the FDA on full approval of their COVID-19 vaccine for people 16 years and older by January 2022.
- On July 13, Johnson & Johnson JNJ and AstraZeneca AZN are researching whether adjusting their COVID-19 vaccines can cut the risk of rare but serious blood clots, according to The Wall Street Journal.
- On July 12, the FDA announced a new warning on the Johnson & Johnson. vaccine and a possible link to Guillain-Barré, a rare autoimmune nerve disorder.
- On July 12, Pfizer said it plans to meet with U.S. health officials to discuss federal authorization of the third dose of its COVID-19 vaccine.
- On June 14, Novavax NVAX said its vaccine candidate hit a 90.4% efficacy rate. The company is filing for FDA authorization in the third quarter.
- On June 1, Moderna MRNA filed for full FDA approval of its COVID-10 vaccine for American adults.
- On May 10, the FDA approved Pfizer PFE & BioNTech's vaccine candidate for emergency use among kids aged 12 to 15.
- On April 23, the FDA and CDC lifted a 10-day “pause” placed on Johnson & Johnson's one-shot vaccine.
Watch the video above to learn more.
Editor's Note: This video was published first published on December 21, 2020. It was updated on July 16, 2021.